HS 1421

Drug Profile

HS 1421

Alternative Names: HS1421

Latest Information Update: 26 Sep 2006

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Class Heart failure therapies
  • Mechanism of Action Atrial peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic nephropathies; Heart failure

Most Recent Events

  • 26 Sep 2006 Discontinued - Preclinical for Diabetic nephropathies in Japan (unspecified route)
  • 26 Sep 2006 Discontinued - Preclinical for Heart failure in USA (unspecified route)
  • 24 Aug 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top